Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus capecitabine vs placebo plus capecitabine in advanced or metastatic breast cancer
2007-000290-32Phase 2Completed
- Sponsor
- SOLTI
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Sorafenib + capecitabine with Placebo + capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Mar 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-000290-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000290-32.